Podcast

Unpacking IO Innovations in Lung Cancer in Pittsburgh

Author(s):

OncLive Staff

In Partnership With:

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer, which featured insights from the UPMC and Fox Chase Cancer Center faculty.

We recently traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Lung Cancer. At the meeting, faculty from the University of Pittsburgh Medical Center and Fox Chase Cancer Center discussed how chemoimmunotherapy has changed the standard of care in stage IV nonsquamous non—small cell lung cancer (NSCLC), highlighted how up-front immunotherapy has become a pivotal part of treatment in squamous NSCLC, and explained how immunotherapy’s success in lung cancer has set the stage for future research.

In addition, faculty examined PD-L1 and tumor mutational burden as biomarkers of immunotherapy response in NSCLC, and provided insight into overcoming acquired resistance to targeted therapy.

Interested in attending an upcoming OncLive® State of the Science Summit™ in your area? Register today.

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.
Related Content
Lung cancer, Image credit: Axel Kock – stock.adobe.com
November 20th 2024

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

Susana M. Campos, MD, MPH
November 21st 2024

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

Parth A. Desai, MBBS, MD
November 20th 2024

Fox Chase Cancer Center Researcher Find New Treatment Targets in Microenvironment of Small Cell Lung Cancer

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

FDA
November 18th 2024

FDA Approves Companion Diagnostic for Tepotinib in mNSCLC Harboring MET Exon 14 Skipping Alterations

Lung cancer, Image credit: Axel Kock – stock.adobe.com
November 18th 2024

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC